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Abstract 
 
Background: Tumor stromal interactions have been shown to be the driving force behind the poor 
prognosis associated with aggressive breast tumors. These interactions, specifically between tumor 
and the surrounding extracellular matrix (ECM), and between tumor and vascular endothelial cells, 
promote tumor formation, angiogenesis, and metastasis to distant tissues. In this study, we develop 
an in vitro vascularized breast tumor platform that allows for investigation of tumor-stromal 
interactions in three aggressive breast tumor derived cell lines: MDA-IBC3, SUM149, and MDA-
MB-231.  
Methods: The in vitro breast tumor platform consists of a cylindrical endothelial vessel, 
surrounded by a tumor cell-seeded collagen matrix allowing for direct interactions between 
endothelial and cancer cells. The platform recapitulates key characteristics of breast tumors, 
including increased vascular permeability, vessel sprouting, and ECM remodeling. Morphological 
and quantitative analysis reveals differential effects from each tumor cell type on endothelial 
coverage, permeability, expression of vascular endothelial growth factor (VEGF), and collagen 
remodeling.  
Results: The triple negative tumors, SUM149 and MDA-MB-321, resulted in a significantly (p 
<0.05) higher endothelial permeability to 70 kda dextran and decreased endothelial coverage of 
the vessel lumen compared to the control TIME only in vitro vascularized platform. 
SUM149/TIME platforms were 1.3 fold lower (p<0.05), and MDA-MB-231/TIME platforms were 
1.5 fold lower (p<0.01) in endothelial coverage compared to the control TIME only platform. 
HER2+ MDA-IBC3 tumor cells expressed high levels of VEGF (p<0.01) and induced vessel 
sprouting without the influence of additional angiogenic supplements or supporting cells. Vessels 
sprouting was tracked over a 3 week period and with increasing time exhibited more pronounced 
formation of multiple vessel sprouts with branches that invaded into the collagen ECM and 
surrounded cluster of MDA-IBC3 cells. Both the IBC cell lines, SUM149 and MDA-IBC3, 
resulted in a collagen ECM with significantly greater porosity with 1.6 and 1.1 fold higher 
compared to control, p<0.01.  
Conclusion: The breast cancer in vitro vascularized platforms introduced in this paper model well-
described in vivo and clinical IBC phenotypes and are an adaptable, high throughout tool for 
unearthing tumor-stromal mechanisms and dynamics behind tumor progression and may prove 
essential in developing effective targeted therapeutics.  
  
Key words: In Vitro, Vasculature, Endothelium, Collagen, Inflammatory Breast Cancer, Triple 
Negative Breast Cancer, HER2+ Breast Cancer, Microfluidics, Sprouting. 
 
Background 
It is now well-established that the tumor microenvironment (TME), which includes various 
proteins including collagen, fibronectin, laminin, and key structures and cells such as vasculature, 
lymphatics, immune cells and various other cell types, are key players in tumor initiation, 
progression, metastasis, chemoresistance, and cancer recurrence [1-6].  Inflammatory breast 
cancer (IBC), invasive and aggressive subtype of locally advanced breast cancer, and is driven by 
tumor-stromal interactions [4, 7-10]. The poor prognosis of IBC, accounting for 10% of all breast 
cancer related mortality, has been linked to IBC tumor-TME interactions which results in its rapid 
development, highly metastatic nature, and chemoresistance [4, 10, 11]. In addition to IBC, studies 
have shown other aggressive malignant breast tumors, to be modulated by tumor-stromal 
interactions. This interaction allows for tumors to remodel their extracellular matrix (ECM) as well 
as impair vascular endothelial barrier function to promote metastasis  [1, 2, 12-20].  
Current pre-clinical experimental models used to study tumor interaction with the TME 
consist primarily of xenograft animal models, two dimensional (2D) monolayers, and three 
dimensional (3D) in vitro models [21-29].  While 2D cell cultures can provide information 
regarding cellular growth, they do not recapitulate the complex and dynamic nature of the tumor 
microenvironment which hosts multi-cellular and cell-matrix interactions, evolving biomechanical 
and biochemical features including matrix stiffening, or pressure and cytokine gradients [30-32]. 
While animal xenografts provide a physiologically relevant in vivo tumor model, determining the 
influence of specific signaling pathways and microenvironmental stimuli on tumor progression is 
challenging and frequently cost prohibitive due to the large number of animals required.  
Additionally, dynamically tracking and quantifying tumor presentation and development at high 
spatial and temporal resolution is limited in animal models. 3D in vitro models have the potential 
to provide a physiologically representative and highly tunable system to study the influence of 
microenvironmental conditions on tumor progression in a dynamic and high throughput manner. 
Avascular 3D in vitro tumor platforms consist of culturing tumor cells on a basement membrane 
or co-culturing with another cell type. These co-culturing experiments are typically evaluated 
under static conditions, thereby lacking physiological flow which has been shown to influence 
tumor response to treatment. [21, 33-35]. Additionally, existing vascularized 3D tumor models 
attempting to recapitulate interactions with the surrounding vessels consist of co-cultures of tumor 
cells with endothelial and stromal cells in a variety of ECMs including collagen, matrigel, and 
fibrin. These experimental models lack a continuous endothelium, or they introduce artificial 
boundaries and fixtures in the ECM such as pillars for structural stability thereby deviating from 
the in vivo tumor architecture [36-40]. Furthermore, these platforms focus on recreating specific 
stages of tumor progression such as initiation, angiogenesis, or metastasis, but not the full timeline 
of tumorigenesis.  Finally, existing platforms are not inclusive of multiple breast cancers subtypes 
cultured under identical conditions, preventing comprehensive comparison of the influence of the 
TME on tumor progression[41-45].  
In this study, we describe the development and characterization of a versatile 3D, in vitro 
vascularized breast tumor platform as a tool for modeling and investigating tumor specific 
responses of aggressive breast cancers, including tumor-stromal interactions with particular 
emphasis of the role of the vasculature and ECM. Understanding the tumor-vasculature and tumor-
ECM interactions are important as they have been shown to direct the disease phenotype and 
impact treatment response [46-52]. We focused on optimizing tumor-endothelial cell assays and 
effects in aggressive IBC (SUM149 and MDA-IBC3) and non-IBC invasive ductal carcinoma 
(MDA-MB-231) breast cancer cells lines. The 3D in vitro vascularized platform was utilized to 
model both tumor cell growth with an optimized intact endothelial cell structure. Conditions 
representative of in vivo tumor vasculature interface such as physiological flow and associated 
shear stress were utilized for development of a continuous, aligned and functional endothelium 
allowing for tumor-endothelial-ECM interactions. We investigated differential effects by cell line 
on endothelial coverage, permeability, and matrix porosity as well as cytokine secretion to 
demonstrate this platform can be used to study spatial and functional interactions not easily 
investigated in existing models. Additionally, we recreated emboli formation and vascular nesting 
of tumor emboli, behavior characteristic of in vivo IBC phenotype.  These platforms provide us 
with a tool to elucidate disease dynamics of aggressive breast cancer tumors where tumor-stroma 
interactions are the driving force behind tumor development and progression. 
 
Materials and Methods 
Cell Culture 
Human breast carcinoma cell line MDA-MB-231(ATCC® HTB-26™) breast carcinoma, 
human breast inflammatory cancer cells MDA-IBC3 and SUM149, and telomerase-immortalized 
human microvascular endothelial (TIME) cells were used in this study. MDA-MB-231 and 
SUM149 are triple negative cell lines while MDA-IBC3 cells are negative for hormone receptors 
but overexpress human epidermal growth factor receptor 2 (HER2).  Stable fluorescent MDA-MB-
231 (GFP) and TIME (mKate) cells were a generous gift from Dr. Shay Soker at the Wake Forest 
Institute for Regenerative Medicine (Winston-Salem, NC).  MDA-IBC3 and SUM149 IBC cell 
lines labeled with GFP were kindly provided by Dr. Wendy Woodward at MD Anderson Cancer 
Center (Houston, TX).  
MDA-MB-231 cells were cultured in Dulbecco’s Modified Eagle’s medium, nutrient 
mixture F-12 (DMEM/F12) (Sigma Aldrich) supplemented with 1% penicillin-streptomycin (P/S) 
(Invitrogen), and 10 % fetal bovine serum (FBS). MDA-IBC3 and SUM149 cells were cultured in 
Ham's F-12 media supplemented with 10% FBS, 1% antibiotic-antimycotic, 1 µg/ml 
hydrocortisone, and 5 µg/ml insulin.  TIME cells were cultured in EBM-2 endothelial growth 
media supplemented with a growth factor BulletKit (Lonza CC-4176). All cell cultures utilized in 
this study were maintained in a 5% CO2 atmosphere at 37°C in an incubator. 
 
In vitro 3D Tumor Platform Fabrication 
The in vitro 3D tumor microfluidic platforms utilized in this study were composed of 
collagen type I matrix seeded with either MDA-MB-231, MDA-IBC3, or SUM 149 with a hollow 
channel seeded with RFP labeled TIME cells housed in a polydimethylsiloxane (PDMS) scaffold. 
Collagen type I extracted from rat tails was prepared following published protocols to produce 
stock collagen concentration of 14 mg/ml which was then neutralized with a solution consisting 
of 10x DMEM, 1N NaOH, and 1x DMEM to produce a final collagen concentration of 7 mg/ml 
comparable to stiffness of breast tumors [53-56]. GFP labeled IBC and non-IBC cells were seeded 
at a density of 1x106 cells/mL in the 7 mg/ml neutralized collagen solution and polymerized around 
a 22G needle at 37°C for 25 minutes. After polymerization, the needle was removed, and the 
resulting hollow void was filled with a solution of 2x105 TIME cells to form an endothelialized 
vessel lumen. The size of the needle can be varied to mimic vessels of varying sizes in a 
controllable manner. Flow was introduced using a syringe pump system and a 72 hour graded flow 
protocol was used to establish a confluent endothelium as we have previously published [53, 56-
58]. Briefly, flow was perfused to expose the endothelium to wall shear stress (WSS) (τ) of 0.01 
dyn/cm2 for 36 hours followed by a gradual increase in WSS to 0.1 dyn/cm2 for the following 36 
hours. After completion of the 72 hour graded flow protocol, the in vitro vascularized platforms 
were exposed to 1 dyn/cm2 for 6 hours.  
 
Endothelial Sprouting 
MDA-IBC3/TIME in vitro vascularized platforms were cultured for an additional three 
weeks following the 78 hour graded flow protocol in order to track endothelial sprouting. 3D 
images of the platforms were acquired using Leica TCS SP8 confocal microscope to observe 
sprout formation and growth. Cross sectional images from the center plane of each channel were 
used to analyze sprout growth and quantified using ImageJ. Fluorescent intensity histograms for 
each image were generated using ImageJ’s plot profile function. Differences between fluorescence 
intensity histograms at each time point were quantified using the two-sample Kolmogorov–
Smirnov (K-S) statistic, a distance measure between each sample pair’s empirical distribution 
functions. The K-S statistic was calculated between the baseline fluorescence intensity distribution 
at Day 0 and subsequent imaging time points and significance was determined using p <0.001. 
 
Immunofluorescent Staining 
 Endothelial morphology and cell-cell junctions were analyzed by performing 
immunofluorescent staining for PECAM-1 and F-actin upon completion of the 78 hour graded 
flow protocol. PECAM-1 (platelet endothelial cell adhesion molecule-1, green) is expressed at 
endothelial intercellular junctions and functions in the maintenance of endothelial barrier functions 
[59]. The staining protocol consisted of perfusing the platforms with 4% paraformaldehyde and 
0.5% triton-X for fixation and permeabilization of the cell membranes, respectively. Next, the 
platforms were incubated in 5% BSA followed by overnight incubation with antibodies for 
PECAM-1 (Abcam, ab215911) and Rhodamine Phalloidin (ThermoFisher, R415). 
 
Endothelium Coverage 
 Vessel volume occupied by TIME cells was quantified using 3D F-actin stained images of 
the endothelium in each co-culture platform with LASX image processing software. Platforms 
containing an endothelial vessel but no cancer cells in the surrounding collagen (TIME only 
platform) served as a control. Reported values for the co-culture platforms were normalized to the 
control. Significance of the data was verified using one-way ANOVA and a 95% confidence 
criterion, p<0.05. 
 
Endothelial Permeability 
Endothelial vessel permeability as a function of paracrine signalling between tumor 
and vasculature was determined by perfusing the channels with 70 kda GFP labelled 
dextran [57, 60]. Four conditions of the 3D in vitro vascularized tumor platforms were 
tested: TIME cell only platform, and platforms consisting of co-culture of TIME cells with 
either MDA-MB-231, MDA-IBC3, or SUM149 cells. After completion of the flow 
protocol for establishing a confluent endothelium, green fluorescent dextran suspended in 
serum free media (10 μg/ml) was perfused through the platforms with images taken every 
five minutes. The average fluorescent intensity was measured from the images and used to 
determine the diffusion permeability coefficient Pd as previously published [57]. Three 
samples (n=3) were used for each platform condition with the resulting permeability factor 
expressed as a mean value ± standard deviation. Significance of the data was verified using 
one-way ANOVA and a 95% confidence criterion. To visualize the differences in 
permeability, the vessels were perfused with blue fluorescent particles and time lapse 
recording of particle perfusion was recorded for 2 hours.  
 
Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was performed to determine collagen matrix porosity 
and observe endothelial adhesion to the collagen matrix. After exposure to 78 hour flow protocol, 
the platforms were fixed in an aldehyde mixture overnight at room temperature followed by 
fixation with osmium on ice for 4 hours. Post fixation, the platforms were dehydrated in an 
ascending series of ethanol solutions (50-70-95%) and then critical point dried by CO2.  Platforms 
were coated with a thin layer of platinum-palladium and high resolution SEM imaging was 
performed with Zeiss Supra40 SEM-Electron Microscope. 
 
Enzyme-linked Immunosorbent assay 
Expression of VEGF, a growth factor known to promote angiogenesis that is excreted from 
endothelial and tumor cells, was measured using enzyme-linked immunosorbent assays (ELISA) 
at two points: upon completion of the graded flow protocol (72 hours) for establishing a confluent 
endothelium and after exposure to WSS of 1 dyn/cm2 (78 hours). 1 ml samples of perfusion media 
were collected from the flow outlet and ELISA was performed as per manufacturer’s protocol 
(R&D Systems, DVE00). Significance of the data was verified using one-way ANOVA and a 95% 
confidence criterion. 
 
Cytokine Analyses 
 Cytokine analyses for CD31, ANG1, ANG2, TGF-α, bFGF, PDGF-bb, EGF, VEGF-A, 
VEGFR3, VEGF-C, TNF-α, IL-8, IL-6, IL-6 Rα, MMP9, MMP2, MMP13 were performed using 
a custom human magnetic luminex assay (R&D Systems). Analyses were performed on platform 
perfusion effluent on Day 0 (end of graded flow protocol) and 3 according to manufacturer’s 
instructions.  Significance of the data was verified using one-way ANOVA and a 95% confidence 
criterion. 
 
 
Results 
In Vitro IBC Platform Development and Characterization 
In vitro 3D Tumor Platform 
The 78 hour flow preconditioning protocol with a graded increase in WSS from 0.01 
dyn/cm2 to 1 dyn/cm2 resulted in a confluent endothelium as shown in Figure 1. Figure 1 shows 
the evolution of the vascular endothelium in the TIME only in vitro vascularized platform. The 
platforms initiated with a vascular channel seeded with rounded clusters of TIME cells (0 hour 
time point) which began to spread out and elongate (24 and 48 hour time points), followed by 
proliferation and alignment of the cells in the direction of flow to ultimately form the confluent 
endothelium observed at the 78 hour time point. The resulting endothelium served as the baseline 
upon which to evaluate the influence of different cancer cells, IBC and non-IBC, on the 
surrounding vessel with respect to endothelial morphology, barrier function, and secretion of 
protumor cytokines. 
Figure 1: Development of the endothelium throughout the flow protocol in a TIME only 
platform. 0 hr time point, taken right after channel formation, initiated with TIME cells in a 
rounded morphology. The subsequent 48 hour of flow promoted TIME cell spreading and 
proliferation followed by alignment of the TIME cells in the direction of flow. The resulting 
confluent endothelium at 78 hours serves to function as a barrier for transendothelial flow. Scale 
bar is 200µm. 
 
In addition to the TIME only in vitro vascularized platform (Figure 2A), platforms with 
co-culture of TIME cells with IBC, MDA-IBC3 (Figure 2B), and SUM149 (Figure 2C), and non-
IBC, MDA-MB-231(Figure 2D) tumor cells were developed and are depicted in Figure 2. The in 
vitro vascularized platforms consist of a mKate labelled TIME seeded vessel lumen (red) 
surrounded by a collagen matrix seeded with GFP labelled cancer cells (green) in the co-culture 
platforms or acellular collagen in the TIME only platform. Co-culture of TIME cells with MDA-
MB-231 and SUM149 cells resulted in a sparsely covered endothelium evidenced by the presence 
of large voids in red signal from the endothelium representing areas of the vessel lumen with no 
endothelial coverage. Both MDA-IBC3/TIME and TIME only in vitro vascularized platforms 
presented a confluent and intact endothelium.  The difference in the tumor cells in the platform 
groups is related to their fluorescent expressions. Emission of the GFP signal from the MDA-IBC3 
is much brighter and stronger compared to the other two cells lines which fluctuate over time. 
Initial cell seeding shown in supplementary Figure A  revealed a similar tumor population in the 
different groups. 
Figure 2: In vitro vascularized breast tumor platforms consisting of monoculture of TIME cell 
seeded lumen (A) or co-culture of GFP labeled (green) MDA-IBC3 (B), SUM149 (C), MDA-MB-
231(D) tumor cells around a TIME cell seeded lumen (red); scale bar: 500 µm. 
 
Endothelium Integrity 
Platforms stained for PECAM-1 and F-actin, as well as SEM analysis illustrated in Figure 
3, demonstrated a compromised endothelium in the in vitro vascularized platforms of 
SUM149/TIME and MDA-MB-231/TIME. Staining patterns of PECAM-1 (green) and F-actin 
(red) in Figures 4A and 4B revealed a bright fluorescent signal present continuously across the 
endothelium in the TIME and MDA-IBC3/TIME in vitro vascularized platforms. However, 
expression of PECAM-1 and actin in SUM149/TIME and MDA-MB-231/TIME was 
discontinuous with regions of endothelium lacking any signal (pointed out by white arrows) 
suggesting formation of intercellular gaps between neighboring endothelial cells which are typical 
of a leaky endothelium. Additionally, F-actin staining of MDA-IBC3/TIME platform displayed 
early signs of angiogenic sprouting with TIME cells starting to bud from the borders of the 
endothelial vessel (boxed areas in Figure 4B) towards MDA-IBC3 cells replicating another 
important phenomenon characteristic of in vivo IBC tumors. This behavior was observed only in 
the MDA-IBC3/TIME platforms. SEM analysis of the endothelium provided high resolution 
images illustrating endothelial morphology and adhesion to the collagen matrix (Figure 4C). 
Endothelial cells in the TIME only and the MDA-IBC3/TIME platforms showed a tight 
endothelium with the endothelial cell edges overlapping between neighboring cells, whereas 
SUM149/TIME and MDA-MB-231/TIME platforms showed voids between adjacent endothelial 
cells as denoted by the white arrows.  
 Figure 3: Immunofluorescent staining of the endothelium: A) PECAM-1 staining of endothelial 
cell-cell junctions (green) with DAPI (blue) staining of cell nuclei for analyzing cell-cell junction 
between neighboring TIME cells; scale bar: 100µm. B) F-actin (red) and DAPI (blue) staining 
revealing morphological difference; scale bar: 200µm. (C)SEM images of endothelial morphology 
and adhesion; scale bar: 10µm.   
 
Quantitative comparison of endothelial coverage of the lumen, Figure 4, exhibited a 
significant decrease in the endothelium coverage in the SUM149/TIME (p<0.05) and MDA-MB-
231/TIME (p<0.01) platforms, compared to the MDA-IBC3/TIME and control platform as 
illustrated in Figure 3. SUM149/TIME had a 1.3 fold and 1.4 fold decrease, and MDA-MB-
231/TIME had a 1.5 and 1.6 fold decrease in endothelial coverage compared to control TIME only 
control and MDA-IBC3/TIME respectively. There was no significant difference between the 
control and the MDA-IBC3/TIME platforms.  
 Figure 4: Endothelium coverage of the vessel lumen of the different co-culture platforms at the 
78 hour time point; values have been normalized to the control TIME only platform. TIME only 
and the MDA-IBC3/TIME platforms had the highest endothelial presence and coverage and MDA-
MB-231/TIME platforms has the least endothelial vessel coverage; *p<0.05, ** p<0.01.   
 
Endothelial Permeability 
Particle flow images in Figure 5A were taken at 1 hour time point and revealed the 
difference in the vessel leakiness. The measured effective permeability for TIME only, MDA-
IBC3/TIME, SUM149/TIME, and MDA-MB-231/TIME platforms were 0.016 ± 0.002, 0.019 ± 
0.002, 0.023 ± 0.002, and 0.025 ± 0.002 respectively, as portrayed in Figure 5B. Vascular 
permeability of the MDA-MB-231/TIME in vitro vascularized platforms were statistically 
significant (p <0.05) with 1.6 and 1.3 fold higher permeability than TIME only and MDA-
IBC3/TIME in vitro vascularized platforms respectively. SUM149/TIME in vitro vascularized 
platform also differed significantly from the TIME only platforms (p< 0.05) with a 1.4 fold 
increase in permeability.  
 Figure 5: Figure 5: A) Qualitative difference in vessel leakiness revealed by perfusion of 
blue fluorescent particles through the vessels. B) Measured effective permeability of 70 
kda green fluorescent dextran perfusion through the in vitro vascularized platforms; 
*p<0.05.  
 
VEGF ELISA  
ELISA measurements for VEGF are illustrated in Figure 6 with the TIME only 
platform serving as the control. VEGF expression was significantly higher (p < 0.01) at 
both time points (72 and 78 hour) in MDA-IBC3/TIME in vitro vascularized platforms 
compared to control (p<0.01) and MDA-MB-231/TIME (p<0.01) and significantly higher 
than SUM149/TIME at 78 hours (p<0.01). VEGF expression in the MDA-IBC3/TIME in 
vitro vascularized platform was 1.6 and 2.0 fold higher at the 72 hour time point and 1.3 
and 3.0 fold higher at the 78 hour time point compared to TIME only and MDA-MB-
231/TIME in vitro vascularized platform respectively. Additionally, there was a trend of 
decrease in mean VEGF expression in the SUM149/TIME and MDA-MB-231/TIME (not 
statistically significant) between the 72 and 78 hour time points.  
 Figure 6: VEGF expression observed at 72 and 78 hour time points. MDA-IBC3/TIME 
platform had a significantly higher VEGF expression compared to control and other co-
culture platforms. Statistical significance at 72 hours is represented by solid lines while 
dotted lines represent 78 hours. *p<0.05, **p<0.01. 
 
Matrix Porosity 
Tumor cell morphology and matrix porosity measurements are illustrated in Figure 
7.  MDA-IBC3 and SUM149 IBC cells displayed an epithelial like rounded phenotype 
while the MDA-MB-231 presented a mesenchymal like phenotype replicating behavior 
found in vivo [61].  Porosity measurements in Figure 7B revealed both the IBC in vitro 
vascularized tumor platforms had a significantly more porous collagen ECM compared to 
MDA-MB-231/TIME and TIME only in vitro vascularized platforms. SUM149/TIME in 
vitro vascularized platforms were 1.5 (p<0.01), 1.6 (p<0.01), and 1.3 (p<0.05) fold higher 
in matrix porosity compared to MDA-MB-231/TIME, TIME only, and MDA-IBC3/TIME 
in vitro vascularized platforms, respectively. MDA-IBC3 in vitro platforms also showed an 
increase in ECM porosity of 1.1 (p<0.05) and 1.2 (p<0.01) fold compared to the MDA-
MB-231/TIME and TIME only platforms.  
 
 Figure 7: A) SEM images of tumor cells morphologies (top panels), and collagen matrix 
organization (bottom panels). B) Collagen matrix porosity measurements calculated from 
SEM images of the ECM, *p<0.05, **p<0.01  
 
Reproduction of Relevant Tumor Biology and Phenotypic Comparisons to Published Models 
Longitudinal Characterization of Vascular Sprouting 
 The resulting sprouting behavior of the MDA-IBC3/TIME in vitro vascularized 
platforms over the three week period is illustrated in Figure 8. Figure 8 revealed the ability 
of the MDA-IBC3/TIME to both promote angiogenic vessel sprouting of the vascular 
endothelium as well the capability of the platform for spatiotemporal tracking of the 
sprouting behavior. On day 0, which represents the endothelium formed after the 78 hour 
graded flow protocol, the endothelium exhibited very few sprouts. At day 4, more sprouts 
were present with TIME cells extending out from the vessel wall into the collagen. By day 
12 and 16, numerous sprouts formed along the length of the vessel wall with multiple 
branches invading deeper into the collagen ECM. The sprouts extended towards clusters of 
MDA-IBC3 cells and started to encircle these clusters leading to formation of and 
proliferation of MDA-IBC3 emboli as pointed out by the white arrows in the Figure 8A 
and in the higher magnification images in Figure 8C. Vascular encircling of MDA-IBC3 
clusters in the in vitro platform is reminiscent of IBC tumors in vivo in both IBC patients 
(Figure 8B) and in patient derived xenograft (PDX) models of IBC [62, 63]. The newly 
formed endothelial sprouts continued to penetrate deeper and further into the collagen ECM 
in a disorganized manner, and the MDA-IBC3 emboli surrounded by the vessels grew 
larger as depicted by the white arrows in the DAY 16 panel and Figure 8B. Quantification 
of vessel sprouting over time showed a significant increase in sprout lengths and growth 
compared to Day 0, p<0.001, (Figure 8C). This phenomenon was only observed in the 
presence of MDA-IBC3 cells and not in any of the other platforms. 
 
Figure 8: Vascular sprouting dynamically observed over a three week period in the MDA-
IBC3/TIME co-culture in vitro vascularized tumor platforms A)Top panel: Longitudinal 
cross section images of the vessel showing vessel sprouting, branching, as well formation 
of tumor emboli (white arrows) scale bar: 200µm; Bottom panel: Front view of the vessels. 
B) CD31 stained vessel (brown) surrounding IBC tumor emboli (blue) derived from patient 
tissue C) mKate labeled vessel (red) surrounding MDA-IBC3 emboli (green) in in vitro 
platform, D) K-S analysis of vessel sprouting revealed a significant increase in sprouting 
at later time points compared to Day 0. 
 Cytokine Analyses of Vascular Sprouting 
Figure 9: Cytokine analysis of various angiogenic associated factors measured over a three 
week period. ANG2, VEGF-A, PDGF-bb, IL-8, IL-6, and MMP2 showed a significant 
increase in expression on Day 22 compared to earlier timepoints while bFGF and EGF both 
peaked on Day 7, *p<0.05. 
 
Cytokine analysis of the perfusion media at outlet illustrated in Figure 9 was 
performed to gain a better understanding of the driving factors behind the sustained 
angiogenic sprouting. VEGF-A, ANG-2, PDGF-bb, IL-8, IL-6, and MMP2 expressions 
were significantly higher (p<0.05) on Day 22 compared to the earlier timepoints. VEGF-A 
expression was higher at the later timepoints (Day 7, 14 and 22) compared to 0 and IL-8 
expression increased significantly on Day 14 and 22 compared to Day 0. bFGF and EGF 
both showed a similar trend with expression peaking on Day 7 (p<0.05) and then decreasing 
back to levels comparable to Day 0 on Day 14 and 22. 
 
 
Discussion 
In this study, we developed 3D in vitro vascularized tumor platforms to model the 
interactions of multiple aggressive breast tumor cell and stroma, specifically tumor-vasculature 
and tumor-ECM interaction. Tumor specific in vivo responses including increased vascular 
permeability, ECM remodeling, and vessel sprouting as a result of the tumor-stromal interaction 
were reproduced and we showed a differential response of the tumors in modulating these 
behaviors. After teasing out the differences between the different tumor cells, we investigated the 
vascular sprouting nature of MDA-IBC3 with the platform providing the first opportunity to 
spatially observe and quantify this behavior in vitro and were able to recreate and validate 
previously published in vivo phenotypes including endothelial sprouting, and vascular encircling 
of tumor emboli.  
Tumor vasculature is characterized by the presence of leaky blood vessels which has been 
implicated in inefficient delivery of chemotherapies as well as playing a crucial role in tumor 
intravasation [64-69]. We demonstrated the presence of triple negative MDA-MB-231 and 
SUM149 cells compromised the vascular barrier functions with formation of large pores and gaps 
in the endothelium as well as decreased endothelial coverage of the vessel. Previous studies 
demonstrated direct contact between MDA-MB-231 and endothelial cells disrupted endothelial 
monolayers and resulted in anoikis of endothelial cells [70-77]. In contrast, MDA-IBC3, did not 
significantly alter the endothelium barrier function and maintained a confluent endothelium. The 
bright patches of red fluorescent signal in the F-actin stained images, as well as the increased 
coverage of the endothelium in MDA-IBC3/TIME in vitro vascularized platform, suggests 
increased proliferation of TIME cells as IBC cells are associated with high proliferation levels of 
endothelial cells [7, 25, 62, 78, 79]. In addition to increased proliferation, IBC is highly angiogenic 
with a significantly higher population of tumor infiltrating and proliferating endothelial cells 
compared to non-IBC cells [62, 79] which is evidenced with the sustained angiogenesis occurring 
and directed towards tumor cells in our MDA-IBC3/TIME in vitro platforms. 
Vascular permeability is a measurement of the integrity and leakiness of the endothelium. 
Co-culture with SUM149 resulted in a significantly increased permeability when compared to the 
platform with TIME cells only. This phenomenon was also mirrored in the MDA-MB-231/TIME 
platform and followed results from multiple groups where introduction of highly invasive tumor 
cells increased permeability of the endothelium [76, 80-87]. The increased vessel permeability 
correlates with the discontinuous expression of PECAM-1, a marker for endothelial cell-cell 
junctions used as a surrogate for permeability and leakiness, in the triple negative in vitro 
vascularized platforms of SUM149/TIME and MDA-MB-231/TIME whereas MDA-IBC3/TIME 
and TIME only in vitro vascularized platforms displayed a uniform expression. Both the SUM149 
and MDA-MB-231 cells disrupt the endothelium resulting in gaps between endothelial cells 
allowing for dextran to cross into the collagen unhindered correlating with results seen in other 
experimental studies [70-77].  
IBC tumors are highly angiogenic with increased expression of angiogenic factors 
as well as a larger density of vascular vessels compared to non-IBC tumors [23, 62, 88-91] 
and as evidenced in our MDA-IBC3/TIME platforms (Figure 8).  VEGF is an 
overexpressed angiogenic factor in IBC and known to influence endothelial growth and 
proliferation and interacts synergistically to induce angiogenesis [23, 55, 91-93]. van Golen 
et al determined increased levels of VEGF mRNA in IBC tumors vs non-IBC tumors [91] 
corresponding with the increased levels of VEGF expression in MDA-IBC3/TIME and 
SUM149/TIME in vitro vascularized platforms compared to MDA-MB-231/TIME. VEGF 
expression was highest in the MDA-IBC3/TIME platform, which displayed angiogenic 
sprouting of the vessel, compared to SUM149/TIME platform which was shown to be 
leakier with decreased endothelial coverage of the vessel no signs of vascular sprouting.  
Co-culture of the tumor and endothelial cells not only affected the vascular integrity 
and cytokine expression, but also influenced ECM properties, specifically porosity. 
Invasive tumors modulate and breakdown the surrounding ECM in order to migrate through 
the TME and out into the surrounding tissue. Normal breast tissue is disorganized with 
random alignment of collagen fibers but in tumors, the collagen fibers are radially oriented 
and organized into thick bundles promoting invasive phenotype [94]. Analysis of SEM 
images of the acellular collagen matrix (data not shown) revealed a pore size of ~1 µm, 
much smaller than cell width. Pore sizes smaller than a cell’s width induces degradation of 
the matrix through secretion of matrix metalloproteinases (MMPs) to allow for motility of 
cancer cells [95-100]. Al-Raawi et al found an overexpression of MMPs by IBC carcinoma 
tissues [101] which are involved in degradation of collagen I and widening of pore size to allow 
for cell migration and invasion [98, 100, 102-105].  Rizwan et al demonstrated an increased 
migratory and invasive behavior in SUM149 cells as well as increased levels of MMP9 in 
compared to MDA-MB-231 cells [18]. Higher proteolytic activity of IBC breast tumors 
compared to non-IBC tumors accounts for the significantly increased matrix porosity in the 
SUM149/TIME and MDA-IBC3/TIME in vitro vascularized platforms.   
To the best of our knowledge, this is the first demonstration of vascular sprouting in a 
3D in vitro platform sustained through interactions between tumor and endothelial cells 
without the influence of any exogenous supplements or additional stromal cells. Along with 
vessel sprouting, we saw the formation and growth of MDA-IBC3 tumor emboli enveloped 
by newly formed vascular vessels which is characteristic of in vivo IBC tumors. In an 
invasion independent metastasis mechanism proposed by Sugino et al, tumor clusters 
accessed blood vessels by being surrounded by the vessels rather than intravasation, similar 
to behavior seen in the MDA-IBC3/TIME vascularized breast tumor platforms (Figure 8C) 
[106]. Published work by Mahooti et al describe a phenotype of encircling vasculogenesis 
in the Mary-X IBC mouse model [63], behavior reproduced by the endothelial sprouts in 
the in vitro platform encircling MDA-IBC3 cells in the matrix demonstrating this in vivo 
phenotype (Figure 8). Analysis of cytokine expression in the MDA-IBC3/TIME platforms 
revealed a significant increase in the proangiogenic factors by Day 22 compare to Day 0 
associated with significant amount of angiogenesis occurring at the later time point. While 
the highest expression of most of the growth factors, cytokine and MMPs measured was 
highest on DAY 22, bFGF and EGF both displayed similar trend in expression levels with 
the highest expression on Day 7. Additionally, we determined VEGF, known as an 
important angiogenic factor [107, 108], to be a key contributor of angiogenesis in our 
system as continued increase in expression of VEGF paralleled the increase in angiogenic 
response in the MDA-IBC3/TIME platform. 
 There are some limitations to our study and the tumor platform presented. While the 
in vitro platforms developed in this study do not encompass the entire complexity of the 
tumor microenvironment and utilize immortalized endothelial cells, they provide an initial 
insight into the behavior of aggressive, metastatic breast tumors. Future experiments 
utilizing this platform can be expanded to incorporate stromal and immune cells known to 
influence tumor behavior. Additionally, we acknowledge that the size of the endothelial 
vessels is larger than the size of in vivo microvasculature, but the platform can be adapted 
to present a more comparable vessel with the use of smaller gauge needles for formation of 
the cylindrical vessels. We have conducted preliminary studies using needles to create 
smaller vessels but vessels below 200 µm using needle subtraction method are not very 
stable. Also, we have started preliminary work looking at the influence of macrophages, 
revealed to be important contributing factor in driving IBC phenotype, and observed their 
role in IBC intravasation and angiogenic response. Future experiments will include 
increasing cellular complexity of the stromal component of the in vitro vascularized 
platform to include mesenchymal stem cells, adipocytes, and fibroblasts. 
  
Conclusion 
3D in vitro vascularized platforms presented in this work allowed us to dynamically 
track and model the tumor-stroma interactions as well as determine the spatiotemporal 
response of these interactions on vascular permeability and matrix porosity for three 
different highly invasive and aggressive breast cancer phenotypes. Both the IBC tumor cells 
were more active in remodeling of the collagen ECM as well as secretion of proangiogenic 
and tumorigenic factor VEGF compared to non IBC MDA-MB-231, revealing potential 
targets for IBC therapeutics. For the first time, we induced angiogenic sprouting of the 
vascular endothelium and vascular surrounding of tumor emboli, characteristic behaviors 
of IBC tumors, purely through interactions between tumor and endothelial cells as well as 
recreated blood vessel leakiness, and increased matrix porosity representative of in vivo 
behavior of invasive tumors. Compared to current 3D in vitro tumor models that focus on 
recreating specific stages of tumor progression, the tumor platforms introduced here were 
able to model various stages in breast cancer progression including early signs of 
angiogenesis as well as modulation of tumor ECM and vasculature for migration and 
metastasis. With the vascularized breast tumor platforms, behavioral variations that are 
representative of in vivo tumors can be identified and differentiated as result of the different breast 
cancer cells. It allows for temporal and spatial imaging and identification of biological proteins 
and responses which may play a direct role in tumorigenesis and vascularization in vivo. They 
represent a useful tool for studying various aggressive breast cancers whose phenotype is 
driven by tumor-stromal interactions. These platforms can be further expanded to include 
increasingly complex cell type interactions to provide a tool by which we can further decipher 
the mechanisms behind development of these tumors and use the knowledge towards 
developing effective and targeted chemotherapies. 
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Supplementary Figure 
 
 
 
Supplementary Figure A: Calcein staining (red) of live GFP tumor cells (green) in the platforms 
without TIME cells 12 hours after initial seeding to visualize cell numbers; scale bar 300µm. All 
cells were seeded at an initial density of 1 million cells/ml. Difference in inherent GFP expression 
are shown as the IBC cells lines MDA-IBC3 and SUM149 express a strong GFP signal while the 
GFP expression of MDA-MB-231 cells is much weaker.  
 
